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Mansour S Al-Said1, Mostafa M Ghorab1* and Yassin M Nissan2Abstract
Several new sulfonebiscompounds having a biologically active 1,2-dihydropyridine-2-one 3–19, acrylamide 20,
chromene 21, 22 and chromenopyridine 23, 24 moieties were synthesized and evaluated as potential anticancer
agents. The structures of the products were confirmed via elemental analyses and spectral data. The screening tests
showed that many of the biscompounds obtained exhibited good anticancer activity against human breast cell line
(MCF7) comparable to doxorubicin which was used as reference drug. Compounds 11, 17 and 24 showed IC50
values 35.40 μM, 29.86 μM and 30.99 μM, respectively. In order to elucidate the mechanism of action of the
synthesized compounds as anticancer agents, docking on the active site of farnesyltransferase and arginine
methyltransferase was also performed and good results were obtained.
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Many naturally occurring and synthetic compounds con-
taining the 2-pyridone scaffold possess interesting
pharmacological properties [1]. The pyridine derivative I,
for example, has been identified as specific non-
nucleuoside reverse transcriptase inhibitor in treatment
of HIV-1 [2,3]. While the pyridine derivatives, Milirinone II
and Amrinone III, and their analouges are used as car-
diotonic agents in the treatment of heart failure [4-7].
Also, Pirfeidione (PFD) IV, a pyridine derivative which
demonstrated antifibrotic activity in several organs in
experimental animals, including lung, kidney and
uterus has proven beneficial cure for a range of fibrotic
conditions through both anti-inflammtory and and
antifibrotic mechanisms [8]. A phase II clinical study
showed PFD to be promising agent for the treatment
of idiopathic pulmonary fibrosis, initiated in mice* Correspondence: mmsghorab@yahoo.com
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reproduction in any medium, provided the ortreated with cyclophosamide [9], amiodarone [10] or belo-
mycin [11-16]. The reported antifbrotic activity of PFD
prompted us to synthesize a new series of sulfonebiscom-
pounds carrying biologically active 1,2-dihydropyridine-2-
one, chromene and chromenopyridine as analoges to PFD.
In addition, some 2-pyridones are also reported to possess
antitumor, antibacterial [17] and other biological activities
[18-20]. On the otherhand, sulfone derivatives have been
found to exhibit a wide variety of pharmacological activ-
ities [21-25]. In addition, the bisheterocyclic compounds
chromenes and chromenopyridine derivatives are well
known as anticancer agents [26-29]. Also, diphenylsul-
fones and bisheterocyclic compounds are reported to have
a broad spectrum of biological activities. Some are
endowed with antitumor or antifungal properties [30]. On
the other hand, some pyridine and isoquinoline derivatives
have various biological properties such as antimicrobial
[31], anticancer [32-35] activities.
Recent studies have proved the remarkable effect of
Dapson on inhibiting cell growth in glioblastoma by act-
ing as anti-VEGF and anti-angiogenic agent via deprivingral Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





























3, Ar = C6H5
4, Ar = C6H4CH3-4
5, Ar = C6H4OCH3-4
6, Ar = C6H4CH=CH2
7, Ar = C6H4NO2-3
8, Ar = C6H4NO2-4
9, Ar = C6H2(OCH3)3
-2,3,4
10, Ar = pipronyl




13, Ar = C6H4N(CH3)2-4
14, Ar = C10H6OCH3
-2
15, Ar = C10H6OCH3-4





Scheme 1 Synthetic pathways used to obtain compounds 2-16.
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http://journal.chemistrycentral.com/content/6/1/64glioblastoma of neutrophil-mediated growth promoting
effects [36]. Allantodapson V, a Dapson derivative showed
high activity as anticancer through inhibition of arginine
methyltranseferase (PRMT1) an enzyme which plays an
important role in hormone dependent cancers. A series of
acylated diarylsulfone derivatives were evaluated for the
same activity and compound VI exihibited good activity as
(PRMT1) inhibitor [37].
In view of these findings, and in continuation to our work
in the synthesis of novel anticancer agents [38-42] we
undertook the synthesis of bisheterocyclicsulfone com-
pounds analogues for 2-pyridones incorporating biologically
active 1,2-dihydropyridine-2-one, chromene, and chrome-











































Biologically active anticancer compounds
Results and discussion
Chemistry
Several compounds were designed with the aim of explor-
ing anticancer properties (Scheme 1, Scheme 2, Scheme 3).
Scheme 1 outlines the synthetic pathway used to obtain
compounds 3–16. The starting material N,N’-(4,4’-sulfonyl-
bis(4,1-phenylene))bis(2-cyanoacetamid) 2 was obtained via
reaction of Dapson 1 with ethyl cyanoacetate. Compound 2
was established by elemental analysis and spectral data.
Thus, IR spectrum of 2 revealed bands at 3448, 3363 cm-1
(2NH), 2256 cm-1 (2 CN), 1701 cm-1 (2 C=O) and
1342, 1180 cm-1 (SO2).
1H-NMR spectrum of 2 in
(DMSO-d6) exhibited signals at 4.0 ppm due to CH2 group,
7.4-7.9 ppm corresponding to aromatic protons and
10.7 ppm due to 2 NH groups. Treatment of compound 2
with appropriate aldehyde and malononitrile in the pres-
ence of catalytic amounts of pipredine compounds 3–16,
respectively. These compounds were verified on the basis
of elemental analyses, IR, 1H-NMR and 13C-NMR. Thus,
IR spectra of compounds 3–16 exhibited the presence of
NH2, CN, C=O and SO2 bands. 1H-NMR spectra of
compounds 3–16 in (DMSO-d6) revealed the presence ofNH2 at 6.0-6.8 ppm and aromatic protons at 6.9-8.7 ppm
(Scheme 1).
Similarly, interaction of 2 with aliphatic aldehyde and
malononitrile in ethanol containing catalytic amount of
piperidine afforded the corresponding 1,2-dihydropyri-
dine-2-one derivatives 17–19. IR spectra of compounds
17–19, exhibited the presence of characteristic bands of
NH2, CN, C=O and SO2 groups 1H-NMR spectrum
of 17 in (DMSO-d6) revealed signals at 6.8 ppm due to
2NH2, while
1H-NMR spectrum of 18 in (DMSO-d6)
revealed signals at 1.8 ppm corresponding to 2CH3. On
the other hand, 1H-NMR spectrum of 19 in (DMSO-d6)
triplet signal at 1.1 ppm for CH3 and a multiplet one at
1.3-2.0 ppm corresponding to CH2 groups. Interaction
of 2 with 2,4-dichlorobenzaldehyde in acetic acid gave
the corresponding acrylamide derivative 20. IR spectrum of
20 revealed bands at 3372 cm-1 (2NH), 2203 cm-1 (2 CN),
1652 cm-1 (2 C=O) and 829 cm-1 (C-Cl). 1H-NMR
spectrum of 20 in (DMSO-d6) showed signals at 8.0 ppm
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Scheme 3 Synthetic pathways used to obtain compounds 21-24.
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http://journal.chemistrycentral.com/content/6/1/64Furthermore, Perkin reaction was carried out by react-
ing compound 2 with salicylaldehyde in acetic anhydride
containing catalytic amount of anhydrous sodium acetate
to give the corresponding chromene derivative 21, while
reaction of 2 with salicylaldehyde in ammonium acetate
afforded 2-iminochromene derivative 22 (Scheme 3).Molecular docking
The zinc-metalloenzyme farnesyl transferase (FTase) cat-
alyzes the transfer of a farnesyl group to a cysteine thiol
group contained in the C-terminal tetra peptide signal
sequence of Ras, frequently referred to as aCAAX motif.
Farnesylation causes membrane localization of Ras
which, in turn, determines the switch from an inactive
to an active Ras-GTP-bound form [43-45]. Among the
Ras isoforms H-ras, N-ras, and K-ras, mutations in the
K-ras isoform are most relevant to human cancers in
particular pancreatic, colon, and lung cancers, which ex-
hibit approximately 90, 40, and 25% incidence of Kras
mutations, respectively. Inhibitors of FTase prevent
membrane localization of the Ras oncogene and have
the ability to revert the transformed phenotype, provid-
ing the rationale for the development of farnesyl trans-
ferase inhibitors (FTIs) as anticancer drugs [46-49].
On the other hand, the relative levels of arginine
methyltransferase (PRMT1) isoforms are altered between
normal and cancerous breast issue, with two of the iso-
forms down-regulated [50]. Therefore, it appears that
PRMT1expression in cancer cells may be altered depend-
ing on the tumor type. Studies are beginning to examine
the specific role of PRMT1in cancer. PRMT1 is an essen-
tial component of a Mixed Line age Leukaemia (MLL)
transcriptional complex that modifies histones by methy-
lation, at H4R3, and acetylation [51]. This serves as the
first demonstration of a direct role for PRMT1-mediated
transcriptional up regulation during cancer progression.
Thus, the present investigation is concerned with the
synthesis of novel anticancer agents and trying to under-
stand their mechanism of action. In order to perform
the aim of the present investigations the authors have
performed molecular docking of the synthesized com-
pounds on the active sites of both farnesyl transferase
and arginine methyltransferase (PRMT1) which may lead
to understanding of their effect as antitumor agents.Molecular docking on the active site of farnesyl transferase
The protein data bank file (PDB:3E30) was selected for
this purpose. The file contains farnesyl transferase en-
zyme co-crystallized with a sulfone ligand. All docking
procedures were achieved by MOE (Molecular Operat-
ing Environment) software 10.2008 provided by chemical
computing group, Canada. Docking on the active site offarnesyl transferase enzyme was performed for all
synthesized compounds 2–24.
Docking protocol was verified by redocking of the co-
crystallized ligand in the vicinity of the active site of the
enzyme with energy score (S) =−25.6345 Kcal/ mol and
root mean standard deviation (RMSD)= 2.8268 (Figure 1).
The sulfone ligand interacts with the active site of far-
nesyl transferase by four interactions: Try B361 with a
hydrogen bond of 2.95 Ao and arene-arene interaction,
Trp 102 with a hydrogen bond of 2.83 and with Zn by
the lone pair of imidazole nitrogen. All synthesized com-
pounds were fit to the active site of farnesyl transferase
enzyme with good energy scores (S) suggesting activity
as farnesyl transferase inhibitors. Energy scores (S) and
amino acid interactions for synthesized compounds were
listed in (Table 1).
Compound 24 showed the best energy score (S)=−45.9317
Kcal/mol and interacted with Lys A146 with a hydrogen
bond of 2.83 Ao, with Arg B202 with two hydrogen bonds
of 2.45, 2.46 Ao and with Zn through its C =O and NH
(Figure 2).Molecular docking on the active site of arginine
methyltransferase (PRMT1)
The protein data bank file (PDB:3Q7E) was selected for
this purpose. The file contains arginine methyltransferase
co-crystallized with its ligand (S-adenosyl methionine). All
docking procedures were achieved by MOE (Molecular
Operating Environment)software 10.2008 provided by
chemical computing group, Canada. Docking on the ac-
tive site of arginine methyltransferase enzyme was
performed for all synthesized compounds 2–24.
Docking protocol was verified by redocking of the co-
crystallized ligand in the vicinity of the active site of the
enzyme with energy score (S)=−18.5932 Kcal/ mol and root
mean standard deviation (RMSD)=0.3523. The ligand inter-
acts with the active site of arginine methyltransferase by five
interactions: Val 128 with a hydrogen bond of 3.00 Ao, with
Arg 54 with a hydrogen bond of 2.64, with Gly 78 with a
hydrogen bond of 1.81 Ao and with Glu 100 with two
hydrogen bonds of 181, 186 Ao (Figure 3).
All synthesized compounds were fit to the active site
of arginine methyltransferase enzyme with good energy
scores (S) except compounds 7, 18 and 19 suggesting
good activity as arginine methyltransferase inhibitors for
most of the synthesized compounds. Energy scores (S)
and amino acid interactions for the synthesized com-
pounds were listed in (Table 2).
Compound 24 showed the best energy score (S)=−23.0582
Kcal/mol and interacted with Arg 327 with two hydrogen
bonds of 2.51, 2.46 Ao, with Lys 127 with a hydrogen
bond of 2.75 Ao and with Glu 130 with a hydrogen bond
of 1.36 Ao (Figure 4).
Table 1 Binding scores and amino acid interactions of the docked compounds on the active site of
farnesyltransferase (FT)
Compound no. S Kcal/Mol Amino acid interactions H bond length Ao Interaction with Zn
2 -22.2685 Leu B295, Lys B294 3.37, 2.76 No interaction
3 -37.4155 Lys A164, Arg B202 3.39, 2.53-3.14 CN
4 -25.1368 Lys B234, Tyr B334, LysB358, Arg B202 3.08, 2.75, 3.28, 2.73 SO2
5 -22.9916 Lys B294, Lys A164, Gln A167, Arg B202 3.47, 2.84, 3.00, 3.09 C=O
6 -31.4218 Lys A164, Arg B202 2.49, 3.28 SO2
7 -30.3616 Arg B291, Arg B202 3.19, 2.47-2.96 CN
8 -26.5141 Arg B291, Lys B294 3.55, 2.94 CN
9 -25.5855 Lys B294, Lys A168, His B362 2.58, 2.76, 3.19 CN
10 -27.1374 Ser B99, Ser B367, Arg B291 3.30, 3.05, 2.56 No interaction
11 -23.4085 Trp B102, Lys A168 2.75, 2.80 C=O
12 -28.7413 Lys A164, Ser B99 3.00, 3.25 CN
13 -27.1676 Lys A164, Arg B202 2.48, 2.76 SO2
14 -28.8232 Lys A164, Arg B202 2.81, 2.89-3.25 C=O
15 -32.2519 Tyr B300, Asn A165 3.10, 3.32 CN
16 -38.0536 Arg B202, Arg B291, Lys B294 2.57, 3.01, 3.39 CN
17 -19.9521 Lys B353, Gly B290, Lys B294, Arg B202 2.78, 3.29, 2.67, 3.13 No interaction
18 -23.0290 Leu B295, Lys B294 3.05, 2.61 No interaction
19 -32.9232 Arg B291 3.81 CN
20 -24.4073 Arg B202 2.35 C=O
21 -29.7807 Tyr B300 2.85 C=O
22 -38.6191 Arg B202, Asp B352 2.92, 1.96 C=O, NH
23 -38.8898 Lys A164, Arg B202 2.81, 2.49-2.55 C=O, C =O
24 -45.9317 Lys A164, Arg B202 2.83, 2.46-2.45 C=O, NH
Figure 1 Co-crystallized sulfone ligand on the active site of farnesyltransferase.
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Figure 2 Compound 24 on the active site of farnesyltransferase.
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The newly synthesized compounds were evaluated for
their in vitro cytotoxic activity against human breast can-
cer cell line; MCF7. Doxorubicin which is one of the most
effective anticancer agents was used as the reference drug
in this study. The relationship between surviving fraction
and drug concentration was plotted to obtain the survival
curve of breast cancer cell line (MCF7).The response par-
ameter calculated was the IC50 value, which corresponds
to the concentration required for 50% inhibition of cell
viability. Table 3 shows the in vitro cytotoxic activity of
the synthesized compounds where all compounds exhib-
ited significant activity compared to the reference drug.
All the synthesized compounds showed better cytotoxic
activity than Doxorubicin except compound 5 which
showed IC50 value 81.22 μM. The 1,2-dihdropyridine-2-one
derivatives 3–19 showed IC50 values in the rang 29.86-
81.22 μM. Compound 17 which showed IC50 value
29.86 μM was the most active compound. Compound 17
also showed good scoring energy S=−19.9521 kcal/Mol.
and the good amino acid interactions upon docking on the
active site of farnesyl transferase enzyme. It also showed
good energy score S=−20.9464 kcal/Mol. and good aminoacid interactions upon docking on the active site of arginine
methyl transferase enzyme. Upon substitution on position
4 of compound 17 with several substitutions the activi-
ty drops. However, 2,3,4-trimethoxy phenyl substitution,
2-chloro phenyl substitution and 4-chloro phenyl substitu-
tion did not decrease the activity in the same way substitu-
tion with 4-CH3 phenyl, 4-OCH3 phenyl and 2-OCH3
naphthyl did. This was clearly illustrated by the values of
IC50 of the 1,2-dihdropyridine-2-one derivatives 9, 11 and
12 with IC50 values of 37.29 μM, 35.40 μM and 40.12 re-
spectively. On the other hand, the IC50 values for the 1,2-
dihdropyridine-2-one derivatives in which the substitution
was with 4-CH3 phenyl, 4-OCH3 phenyl and 2-OCH3
naphthyl were much higher indicating less activity. This
was clearly shown in the 1,2-dihydropyridine derivatives 4,5
and 14 with IC50 values of 54.37 μM, 81.22 μM and
65.58 μM, respectively.
Compounds 20–24 showed cytotoxic activity with IC50
values in the range of 30.99 to 56.37 μM with cytotoxic ac-
tivity better than that of Doxorubicin. The chromenopyri-
dine derivative 24 was with the best IC50= 30.99 μM
among these compounds while compound 23 showed the
highest IC50 value 56.37 μM among these compounds.
Figure 3 Co-crystallized S-adenosyl methionine ligand on the active site of arginine methyltransferase (PRMT1).
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S=−45.9317 kcal/Mol. and the best amino acid interac-
tions upon docking on the active site of farnesyl transfer-
ase enzyme. It also showed the best energy score
S=−23.0582 kcal/Mol. and the best amino acid interac-
tions upon docking on the active site of arginine methyl
transferase enzyme.
The promising results of cytotoxic activity of the synthe-
sized compounds especially compounds 17, 24 urge more
investigations for their mechanism of action. The trial in
the present investigation to predict an assumption of the
mechanism of action of the synthesized compounds was
conducted through molecular docking on the active site of
two enzymes based on the similarities between the synthe-




Melting points (°C, uncorrected) were determined in open
capillaries on a Gallenkemp melting point apparatus (SanyoGallenkemp, Southborough, UK) and were uncorrected.
Precoated silica gel plates (silica gel 0.25 mm, 60 GF254;
Merck, Germany) were used for thin layer chromatog-
raphy, dichloromethane/methanol (9.5:0.5) mixture was
used as a developing solvent system and the spots were
visualized by ultraviolet light and/or iodine. Infra-red spec-
tra were recorded in KBr discs using IR-470 Shimadzu
spectrometer (Shimadzu, Tokyo, Japan). NMR spectra
(in DMSO-d6) were recorded on Bruker AC-300 Ultra
Shield NMR spectrometer (Bruker, Flawil, Switzerland, δ
ppm) at 300 MHz using TMS as internal Standard and
peak multiplicities are designed as follows: s, singlet;
d, doublet; t, triplet; m, multiplet. Elemental analyses
were performed on Carlo Erba 1108 Elemental Analyzer
(Heraeus, Hanau, Germany).
N,N'-(4,4'-sulfonylbis(4,1-phenylenebis (2-cyanoace-
tamide) 2 A mixture of Dapsone (2.48 g, 0.01 mol.) and
ethyl cyanoacetate (1.13 g, 0.01 mol.) was refluxed for
3 h, concentrated and cooled. The obtained solid was
Table 2 Binding scores and amino acid interactions of the docked compounds on the active site of arginine
methyltransferase (PRMT1)
Compound no. S Kcal/Mol Amino acid interactions H bond length Ao
2 -20.0584 Lys 127, His 293 2.65, 2.81
3 -13.8464 Lys 127, Arg 327 2.39, 2.96
4 -17.2063 Lys 127, Arg 327 2.42-2.39, 2.45
5 -13.6909 Lys 127, His 45, Arg 327 2.57, 2.95, 2.36
6 -18.0294 Arg 327 2.45-3.02
7 11.0959 —————————— ——————————
8 -15.9006 Lys 127, Arg 327 2.40, 2.30
9 -5.1052 His 45, Glu 153, Arg 327 2.75, 1.65, 2.36
10 -17.1347 Lys 127, Glu 153, His 45 2.75, 1.58, 2.87
11 -12.0837 Asn 167 2.65
12 -19.6261 Lys 127, Arg 327 2.59-2.84, 2.85
13 -15.7402 Lys 127, Glu 153, Arg 327 2.47, 1.93, 2.44
14 -20.4078 Asn 157, Lys 127 3.18, 2.66-2.79
15 -18.8629 Gln 163, Lys 127 2.22, 2.42-3.23
16 14.8212 —————————— ——————————
17 -20.6494 Asn 157, His 45, Lys 127 3.24, 3.21, 2.68
18 6.1835 —————————— ——————————
19 10.1989 —————————— ——————————
20 -17.2838 Lys 127 2.51
21 -17.6535 Lys 127 2.51, 2.86
22 -15.4395 Arg 327, Glu 144 2.79, 1.47
23 -19.4615 Lys 127 2.54, 2.52
24 -23.0582 Arg 327, Lys 127, Glu 130 2.51-2.46, 2.75, 1.36
Figure 4 Compound 24 on the active site of arginine methyltransferase (PRMT1).
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Table 3 In vitro anticancer screening of the synthesized
compounds against human breast cell line (MCF7)
Comp NO. Compound concentration (μM) IC50
(μM)10 μM 25 μM 50 μM 100 μM
Surviving fraction (Mean± S.E.)*
Doxorubicin 0.721± 0.02 0.546 ± 0.02 0.461± 0.01 0.494 ± 0.03 71.80
2 0.727± 0.134 0.427 ± 0.055 0.307± 0.029 0.317 ± 0.021 46.57
3 0.793± 0.055 0.454 ± 0.097 0.292± 0.008 0.332 ± 0.050 52.45
4 0.840± 0.063 0.435 ± 0.035 0.403± 0.015 0.335 ± 0.082 54.37
5 0.906± 0.021 0.642 ± 0.059 0.428± 0.038 0.547 ± 0.046 81.22
6 0.732± 0.333 0.584 ± 0.046 0.406± 0.069 0.229 ± 0.097 49.65
7 0.761± 0.190 0.546 ± 0.123 0.254± 0.031 0.297 ± 0.048 47.83
8 0.830± 0.124 0.399 ± 0.082 0.199± 0.021 0.272 ± 0.005 42.56
9 0.649± 0.028 0.394 ± 0.339 0.207± 0.027 0.261 ± 0.049 37.29
10 0.609± 0.059 0.479 ± 0.095 0.332± 0.058 0.316 ± 0.064 45.45
11 0.747± 0.197 0.359 ± 0.052 0.153± 0.020 0.189 ± 0.002 35.40
12 0.604± 0.075 0.232 ± 0.019 0.376± 0.089 0.312 ± 0.029 40.12
13 0.650± 0.184 0.401 ± 0.016 0.253± 0.021 0.401 ± 0.017 45.77
14 0.875± 0.066 0.580 ± 0.046 0.336± 0.049 0.467 ± 0.047 65.58
15 0.886± 0.047 0.423 ± 0.024 0.259± 0.054 0.389 ± 0.047 52.48
16 0.669± 0.114 0.539 ± 0.088 0.276± 0.064 0.259 ± 0.080 44.62
17 0.509± 0.235 0.230 ± 0.139 0.300± 0.134 0.279 ± 0.065 29.86
18 0.865± 0.057 0.615 ± 0.048 0.232± 0.046 0.286 ± 0.071 50.74
19 0.815± 0.042 0.545 ± 0.109 0.264± 0.044 0.336 ± 0.096 51.48
20 0.703± 0.189 0.427 ± 0.194 0.251± 0.026 0.374 ± 0.085 46.26
21 0.941± 0.020 0.472 ± 0.209 0.199± 0.090 0.278 ± 0.108 47.49
22 0.653± 0.291 0.574 ± 0.180 0.337± 0.116 0.359 ± 0.044 52.74
23 0.878± 0.032 0.563 ± 0.065 0.276± 0.031 0.389 ± 0.058 56.37
24 0.648± 0.329 0.280 ± 0.154 0.174± 0.105 0.194 ± 0.065 30.99
* Each value is the mean of three values ± Standard Error.
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92%, melting point 137.5-139°C. IR:υmax./cm
-1 3448, 3363 (2
NH), 3062 (CH aromatic), 2960, 2931 (CH aliphatic), 2256
(CN), 1701 ( 2 C=O),1342, 1180 (SO2).
1H-NMR (DMSO-
d6, D2O):δ 4.0 (s, 4 H, 2CH2), 7.4-7.9 (m, 8 H, Ar-H), 10.7
(s, 2 H, 2NH exch.). 13C-NMR(DMSO-d6, D2O): 24.4(2),
115.6(2), 119.2(2), 119.3(2), 128.1(2), 129.2(2), 137.8(2),
142.7(2), 162.2(2). Anal. Calcd. for C18H14N4O4S (382.39):
C, 56.54; H, 3.69; N, 14.65. Found: C, 56.81; H, 3.84; N, 14.29.General procedure for compounds 3–16 and 17–19
A mixture of the starting material 2 (6.86 g, 0.01 mol.),
appropriate aldehydes (0.01 mol.) and malononitrile
(0.66 g, 0.01 mol.) in ethanol (50 mL) containing catalytic
amount of piperidine in ethanol (50 mL) was heated under
reflux for 5 h. The obtained solid was crystallized from
dioxane to give 3–19, respectively.1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-
oxo-4-phenyl-1,2-dihydropyridine-3,5-dicarbonitrile) 3
Yield 68%, melting point 257.7-259°C. IR:υmax./cm
-1
3448, 3371 (2 NH2), 3077 (CH aromatic), 2210 (2 CN),
1670 (2 C=O),1290 (2 C=S), 1399, 1149 (SO2).
1H-NMR
(DMSO-d6, D2O):δ 6.2 (s, 4 H, 2NH2, exch.), 7.4-7.9
(m, 18 H, Ar-H). Anal. Calcd. for C38H22N8O4S(686.70):
C, 66.46; H, 3.23; N, 16.32. Found: C, 66.71; H, 3.20; N, 16.00.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-
oxo-4-p-tolyl-1,2-dihydropyridine-3,5-dicarbonitrile)
4 Yield 76%, melting point 234.2°C. IR:υmax./cm
-1 3371,
3209 (2 NH2), 3100 (CH aromatic), 2960, 2870 (CH ali-
phatic),2218 (2 CN), 1674 (2 C=O), 1400, 1149
(SO2).
1 H-NMR (DMSO-d6, D2O):δ 2.4 (s, 6 H, 2 CH3),
6.6 (s, 4 H, 2NH2, exch.), 7.3-8.1 (m, 16 H, Ar-H).
13 C-
NMR(DMSO-d6, D2O): 17.6 (2), 80.2 (2), 114.2 (2), 115.6
(4), 128.0 (4), 128.6 (4), 130.1 (4), 131.0 (4), 133.8 (4),
134.7 (4), 152.8 (2), 153.9 (2), 163.4 (2). Anal. Calcd. for-
C40H26N8O4S(714.75): C, 67.22; H, 3.67; N, 15.68. Found:
C, 67.56; H, 3.44; N, 15.50.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3,5-
dicarbonitrile) 5 Yield 71%, melting point >340°C.
IR:υmax./cm
-1 3390, 3210 (NH, NH2),3100 (CH aro-
matic), 2962, 2839 (CH aliphatic), 2214 (2 CN), 1680
(2 C=O), 1400, 1180 (SO2).
1 H-NMR (DMSO-d6,
D2O):δ 3.8 (s, 6 H, 2 OCH3), 6.3 (s, 4 H, 2NH2, exch.),
7.0-8.1 (m, 16 H, Ar-H). 13 C-NMR(DMSO-d6, D2O):
55.2 (2), 77.9 (2), 113.7 (4), 117.6 (2), 117.9 (4), 127.5 (4),
129.1 (2), 129.5 (4), 130.8 (4), 140.6 (2), 141.2 (2), 157.7
(2), 159.6 (2), 160.3 (2), 160.8 (2). Anal. Calcd. for-
C40H26N8O6S(746.75): C, 64.34; H, 3.51; N, 15.01.
Found: C, 64.24; H, 3.19; N, 15.38.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-oxo-
4-styryl-1,2-dihydropyridine-3,5-dicarbonitrile) 6 Yield
79%, melting point 235.8°C. IR:υmax./cm
-1 3448, 3370
(2NH2),2939,2860 (CH aliph.), 2218 (2 CN), 1685
(2 C=O), 1390, 1149 (SO2).
1 H-NMR (DMSO-d6,
D2O):δ 6.6, 6.9 (2d, 4 H, 2 CH=CH, J = 7.4,7.3 Hz),
7.0-7.8 (m, 22 H, Ar-H+ 2NH2, exchangable).
13C-NMR
(DMSO-d6): 62.9(2), 101.8(2), 113.0(4), 120.7(4), 125.7
(2), 126.8(4), 128.1(2), 128.5(4), 129(4), 131.9(2), 133.7
(2), 137.2(2), 138.8(2), 154.3(2), 155.9(2), 176.1(2).
Anal. Calcd. for C42H26N8O4S(738.77): C, 68.28; H,
3.55; N, 15.17. Found: C, 68.53; H, 3.61; N, 14.92.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(3-nitrophenyl)-2-oxo-1,2-dihydropyridine-3,5-dicarbo-
nitrile) 7 Yield 81%, melting point 167.2°C. IR:υmax./cm
-1
3375, 3213 (2 NH2), 3093 (CH arom.), 2218 (2 CN),
1674 (2 C=O), 1350, 1149 (SO2), 1593, 1330 (NO2).
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http://journal.chemistrycentral.com/content/6/1/641H-NMR (DMSO-d6, D2O):δ 6.6 (s, 4 H, 2NH2,
exchangable), 7.5-8.4 (m, 16 H, Ar-H). 13 C-NMR
(DMSO-d6): 75.6(2), 113.0(2), 116.7(4), 122.8(2), 124.8
(4), 125.1(2), 128.8(4), 129.8(2), 134.5(2), 136.0(2), 137.2(2),
138.4(2), 147.7(2), 156.9(2), 159.1(2), 165.5(2). Anal. Calcd.
for C38H20N10O8S(776.69): C, 58.76; H, 2.60; N, 18.03.
Found: C, 58.90; H, 2.91; N, 17.89.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(4-nitrophenyl)-2-oxo-1,2-dihydropyridine-3,5-dicarbo-
nitrile) 8 Yield 72%, melting point 208.0°C. IR:υmax./cm
-1
3371, 3210 (2 NH2), 3100 (CH arom.), 2194 (2 CN),
1674 (2 C=O), 1346, 1149 (SO2), 1593, 1332 (NO2).
1 H-NMR (DMSO-d6, D2O):δ 6.7 (s, 4 H, 2NH2,
exchangable), 7.8-8.4 (m, 16 H, Ar-H). 13 C-NMR
(DMSO-d6): 73.7(2), 114.4(2), 114.9(4), 124.5(4), 127.9
(4), 129.1(4), 130.2(4), 137.6(2), 138.9(2), 141.1(2), 144.6
(2), 156.8(2), 157.3(2), 166.9(2). Anal. Calcd. for
C38H20N10O8S(776.69): C, 58.76; H, 2.60; N, 18.03.
Found: C, 59.00; H, 2.78; N, 18.09.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-
oxo-4-(2,3,4-trimethoxyphenyl)-1,2-dihydropyridine-3,5-
dicarbonitrile) 9 Yield 70%, melting point 286.4°C.
IR:υmax./cm
-1 3378, 3210 (2 NH2), 3097 (CH arom.),
2943, 2839(CH aliph.), 2218 (2 CN), 1674 (2 C=O),
1390, 1157 (SO2).
1 H-NMR (DMSO-d6, D2O):δ 3.7, 3.8
(2 s, 18 H, 6OCH3), 6.7 (s, 4 H, 2NH2, exchangable),
6.9-8.0 (m, 12 H, Ar-H). 13 C-NMR(DMSO-d6): 55.8(2),
55.9(2), 60.5(2), 76.7(2), 107.7(2), 113.3(2), 115.4(2),
116.1(4), 121.1(2), 124.9(4), 129.8(4), 130.6(2), 138.9(2),
141.8(2), 150.1 (2), 153.5(2), 156.4(2), 159.6(2), 165.9(2).
Anal. Calcd. for C44H34N8O10S(866.85): C, 60.96; H,
3.95; N, 12.93. Found: C, 60.72; H, 4.03; N, 12.81.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(benzo[d][1,3]dioxol-5-yl)-2-oxo-1,2-dihydropyridine-
3,5-dicarbonitrile) 10 Yield 77%, melting point 291.6°C.
IR:υmax./cm
-1 3313, 3197 (2 NH2), 3100 (CH arom.),
2912, 2836(CH aliph.), 2214 (2 CN), 1686 (2 C=O),
1390, 1195 (SO2).
1 H-NMR (DMSO-d6, D2O):δ 6.1
(s, 4 H, 2CH2), 6.3 (s, 4 H, 2NH2, exchangable), 7.0-8.0
(m, 14 H, Ar-H). 13 C-NMR(DMSO-d6): 79.1(2), 102.4
(2), 109.1(2), 113.9(2), 115.7(2), 116.2(4), 120.5(2), 125.7
(4), 128.3(2), 128.4(4), 136.0(4), 148.1(4), 151.2(2), 161.3
(2), 164.9 (2). Anal. Calcd. for C40H22N8O8S(774.72): C,




bonitrile)11 Yield 69%, melting point 251.4°C. IR:υmax./
cm-1 3380, 3213 (2 NH2), 3097 (CH arom.), 2222 (2 CN),
1678 (2 C=O), 1380, 1153 (SO2), 740 (C-Cl).
1H-NMR(DMSO-d6, D2O):δ 6.6 (s, 4 H, 2NH2, exchangable), 7.4-7.9
(m, 16 H, Ar-H). 13C-NMR(DMSO-d6): 76.2(2), 114.8(2),
115.4(4), 124.6(4), 128.7(2), 129.8(2), 130.1(4), 130.3(2),
130.6(2), 131.7(2), 133.8(2), 138.7(2), 141.9(2), 153.7(2),
156.7(2), 159.4(2). Anal. Calcd. for C38H20Cl2N8O4S




dicarbonitrile)12 Yield 86%, melting point 313.1°C.
IR:υmax./cm
-1 3387, 3329 (2 NH2), 3093 (CH arom.), 2187
(2 CN), 1660 (2 C=O), 1370, 1161 (SO2), 771 (C-Cl).
1H-NMR (DMSO-d6, D2O):δ 6.6 (s, 4 H, 2NH2, exchang-
able), 7.5-8.1 (m, 16 H, Ar-H). 13 C-NMR(DMSO-d6):
80.2(2), 114.2(2), 115.6(4), 123.6(4), 128.7(4), 128.9(4),
130.0(4), 130.1(4), 134.8(4), 158.8(2), 153.9(2), 163.4(2).
Anal. Calcd. for C38H20Cl2N8O4S(755.59): C, 60.40; H, 2.67;
N, 14.83. Found: C, 60.71; H, 2.38; N, 15.08.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(4-(dimethylamino)phenyl)-2-oxo-1,2-dihydropyr-
idine-3,5-dicarbonitrile)13 Yield 71%, melting point
277.4°C. IR:υmax./cm
-1 3464, 3367 (2 NH2), 3097 (CH
arom.), 2908, 2870 (CH aliph.), 2210 (2 CN), 1678
(2 C=O), 1381, 1168 (SO2).
1H-NMR (DMSO-d6, D2O):δ
3.0 (s, 12 H, 4 CH3), 6.8 (s, 4 H, 2NH2, exchangable), 7.5-8.0
(m, 16 H, Ar-H). 13C-NMR(DMSO-d6): 40.1(4), 78.1(2),
112.9(4), 117.8(2), 118.4(4), 120.2(2), 125.8(4), 128.2(4), 129.2
(4), 127.6(2), 143.2(2), 151.4(2), 153.4(2), 162.2(2), 162.3(2).
Anal. Calcd. for C42H32N10O4S(772.83): C, 65.27; H, 4.17; N,
18.12. Found: C, 65.50; H, 4.00; N, 18.41.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
(2-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3,5-
dicarbonitrile)14 Yield 70%, melting point 269.6°C.
IR:υmax./cm
-1 3448, 3367 (2 NH2), 3066 (CH arom.),
2935, 2870 (CH aliph.), 2183 (2 CN), 1678 (2 C=O),
1350, 1149 (SO2).
1 H-NMR (DMSO-d6, D2O):δ 3.9 (s,
6 H, 2 OCH3), 6.6 (s, 4 H, 2NH2, exchangable), 7.3-8.1
(m, 16 H, Ar-H). Anal. Calcd. for C40H26N8O6S(746.75):




dicarbonitrile)15 Yield 76%, melting point 303.8°C.
IR:υmax./cm
-1 3317, 3197 (2 NH2), 3070 (CH arom.),
2339, 2843 (CH aliph.), 2214 (2 CN), 1686 (2 C=O),
1370, 1149 (SO2).
1 H-NMR (DMSO-d6, D2O):δ 3.9 (s,
6 H, 2 OCH3), 6.3 (s, 4 H, 2NH2, exchangable), 7.0-8.3
(m, 16 H, Ar-H). 13 C-NMR(DMSO-d6): 56.0(2), 80.2(2),
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131.3(4), 133.1(4), 133.6(2), 134.2(4), 134.8(2), 151.3(2),
152.8(2), 153.8(2), 163.4(2). Anal. Calcd. for C40H26N8O6S
(746.75): C, 64.34; H, 3.51; N, 15.01. Found: C, 64.48;
H, 3.70; N, 14.92.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-
oxo-4-(thiophen-2-yl)-1,2-dihydropyridine-3,5-dicarbo-
nitrile)16 Yield 81%, melting point 187.7°C. IR:υmax./cm
-
1 3375, 3213 (2 NH2), 3100 (CH arom.), 2214 (2 CN),
1676 (2 C=O), 1390, 1149 (SO2).
1H-NMR (DMSO-d6,
D2O):δ 6.6 (s, 4 H, 2NH2, exchangable), 7.2-8.7 (m,
14 H, Ar-H). 13 C-NMR(DMSO-d6): 75.3(2), 116.2(4),
120.5(2), 127.2(2), 127.7(2), 128.7(2), 129.8(4), 130.4(2),
135.6(2), 138.1(2), 144.6(2), 153.5(2), 162.1(2), 171.9(2).
Anal. Calcd. for C34H18N8O4S3(698.75): C, 58.44; H,
2.60; N, 16.04. Found: C, 58.19; H, 2.90; N, 16.32.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-2-
oxo-1,2-dihydropyridine-3,5-dicarbonitrile)17 Yield
66%, melting point 308.9°C. IR:υmax./cm
-1 3371, 3206 (2
NH2), 2187 (2 CN), 1680 (2 C=O), 1377, 1145
(SO2).
1 H-NMR (DMSO-d6, D2O):δ6.8 (s, 4 H, 2NH2,
exchangable), 7.6-7.8 (m, 10 H, Ar-H+ 2CH pyridone).
13 C-NMR(DMSO-d6): 62.9(2), 100.2(2), 116.2(4), 122.9
(4), 130.2(4), 136.9(2), 139.6(2), 151.7(2), 154.2(2), 158.7
(2). Anal. Calcd. for C26H14N8O4S(534.51): C, 58.42; H,
2.64; N, 20.96. Found: C, 58.60; H, 2.88; N, 20.71.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
methyl-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile)
18 Yield 68%, melting point 230.2°C. IR:υmax./cm
-1 3410,
3394 (2 NH2), 2935, 2860 (CH aliph.), 2198 (2 CN),
1686 (2 C=O), 1390, 1149 (SO2).
1H-NMR (DMSO-d6,
D2O):δ 1.6 (s,6 H, 2 CH3), 6.7 (s, 4 H, 2NH2, exchang-
able), 7.3-8.0 (m, 8 H, Ar-H). 13 C-NMR(DMSO-d6): 8.4
(2), 56.2(2), 114.9(2), 116.2(4), 119.5(4), 128.1(4), 136.7
(2), 136.9(2), 151.2(2), 152.8(2), 166.9(2). Anal. Calcd. for
C28H18N8O4S(562.56): C, 59.78; H, 3.23; N, 19.92.
Found: C, 59.54; H, 3.40; N, 19.69.
1,1'-(4,4'-sulfonylbis(4,1-phenylene))bis(6-amino-4-
butyl-2-oxo-1,2-dihydropyridine-3,5-dicarbonitrile)19
Yield 62%, melting point 236.3°C. IR:υmax./cm
-1 3380,
3367 (2 NH2), 2954, 2840 (CH aliph.), 2195 (2 CN),
1650 (2 C=O), 1399, 1149 (SO2).
1H-NMR (DMSO-d6,
D2O):δ 1.1 (t,6 H, 2 CH3), 1.3-2(m,12 H,6 CH2), 6.6 (s,
4 H, 2NH2, exchangable), 7.3-7.9 (m, 8 H, Ar-H).
13 C-
NMR(DMSO-d6): 13.5(2), 21.7(2), 22.3(2), 29.1(2), 62.6
(2), 113.5(2), 113.9(4), 120.8(4), 129.1(4), 133.9(2), 142.3(2),
153.6(2), 161.6(2), 175.8(2). Anal. Calcd. for C34H30N8O4S
(646.72): C, 63.14; H, 4.68; N, 17.33. Found: C, 63.00; H,
4.90; N, 17.01.(2E,2'E)-N,N'-(4,4'-sulfonylbis(4,1-phenylene))bis(2-
cyano-3-(2,4-dichlorophenyl)acrylamide) 20 A mixture
of 2 (3.82 g, 0.01 mol.) and 2,4-dichlorobenzaldehyde
(3.50 g, 0.02 mol.) in acetic acid was refluxed for 8 h, the
obtained solid was filtered and recrystallized from acetic
acid to give 20. Yield 88%, melting point 253.4°C.
IR:υmax./cm
-1 3372 (2 NH), 3986 (CH arom.), 2940, 2860
(CH aliph.), 2203 (2 CN), 1652 (2 C =O), 1390, 1145
(SO2), 829 (C-Cl).
1 H-NMR (DMSO-d6, D2O):δ6.9-7.8
(m, 14 H, Ar-H), 10.0 (s, 2 H, 2NH, exchangable). 13 C-
NMR(DMSO-d6): 112.8(2), 119.0(2), 122.8(4), 127.9(2), 128.5
(4), 129.0(2), 130.1(2), 130.4(2), 132.6(2), 134.6(2), 135.9(2),
142.8(2), 153.3(2), 163.3(2). Anal. Calcd. for C32H18Cl4N4O4S
(696.39): C, 55.19; H, 2.61; N, 8.05. Found: C, 55.36; H, 2.50;
N, 7.99.
N,N'-(4,4'-sulfonylbis(4,1-phenylene))bis(2-oxo-2 H-
chromene-3-carboxamide) 21 To a solution of 2 (3.82 g,
0.01 mol.) in acetic anhydride (30 mL), salicylaldehyde
(2.44 g, 0.02 mol.) and fused Na acetate (1.6 g, 0.02 mol.)
were added, the reaction mixture was refluxed for 3 h,
cooled and the solid obtained was crystallized from
dioxane to give 21. Yield 59%, melting point 195.5°C.
IR:υmax./cm
-1 3433 (2 NH), 3097 (CH arom.), 1762,
1720 (4 C =O), 1396, 1157 (SO2).
1 H-NMR (DMSO-d6,
D2O):δ 7.3-7.6 (m, 16 H, Ar-H), 8.2 (s, 2 H, 2CH), 10.4
(s, 2 H, 2NH, exchangable). 13C-NMR(DMSO-d6): 118.9(2),
121.8(2), 123.3(2), 124.4(4), 126.4(2), 127.7(2), 128.8(2),
130.7(4), 137.6(2), 141.2(2), 144.3(2), 152.1(2), 169.1(2),
171.9(2). Anal. Calcd. for C32H20N2O8S(592.57):C, 64.86; H,
3.40; N, 4.73. Found: C, 64.76; H, 3.31; N, 5.00.
N,N'-(4,4'-sulfonylbis(4,1-phenylene))bis(2-imino-
2 H-chromene-3-carboxamide) 22 A mixture of com-
pound 2 (3.82 g, 0.01 mol.), salicylaldehyde (2.44 g,
0.02 mol.) and anhydrous ammounium acetate (2.30 g,
0.03 mol.) was refluxed in ethanol (50 mL) for 2 h. The
solid obtained was crystallized from ethanol to give 22.
Yield 64%, melting point 256.1°C. IR:υmax./cm
-1 3383,
3259 (4 NH), 1686 (2 C =O), 1377, 1149 (SO2).
1 H-NMR
(DMSO-d6, D2O):δ 7.2-8.0 (m, 16 H, Ar-H), 8.6 (s, 2 H,
2CH), 10.4 (s, 2 H, 2NH, exchangable), 13.1 (s, 2 H, 2NH,
exchangable),. 13C-NMR(DMSO-d6): 114.9(2), 119.7(2), 122.2
(2), 122.5(4), 125.7(2), 127.9(2), 128.8(2), 129.4(4), 134.1(2),
141.6(2), 142.1(2), 153.7(2), 160.2(2), 165.5(2). Anal. Calcd. for
C32H22N4O6S(590.61): C, 65.08; H, 3.75; N, 9.49. Found: C,
65.23; H, 3.60; N, 9.29.
General procedure for synthesis of compound 23 and 24
Equimolar amount of compound 21or 22 (0.01 mol.)
and malononitrile (1.32 g, 0.02 mol.) and anhydrous am-
monium acetate (2.30 g, 0.03 mol.) were refluxed in
ethanol (50 mL) for 5 h. The obtained solid was crystal-
lized from dioxane to give 23 and 24, respectively.
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dioxo-4,5-dihydro-3 H-chromeno[3,4-c]pyridine-1-
carbonitrile) 23 Yield 75%, melting point 267.8°C.
IR:υmax./cm
-1 3444, 3344 (2 NH2), 3100 (CH arom.),
2199 (2 CN), 1690, 1660 (4 C=O), 1373, 1153 (SO2).
1H-NMR (DMSO-d6, D2O):δ 6.7 (s, 4 H, 2NH2, exchang-
able), 7.1-8.0 (m, 16 H, Ar-H). 13C-NMR(DMSO-d6): 76.7
(2), 115.8(2), 119.0(2), 121.8(2), 122.6(4), 123.9(2), 124.8
(2), 128.3(4), 129.0(2), 135.0(4), 141.1(2), 143.5(2), 158.0
(2), 158.4(2), 164.8(2), 169.1(2), 170.3(2). Anal. Calcd. for
C38H20N6O8S(720.67): C, 63.33; H, 2.80; N, 11.66. Found:
C, 63.11; H, 2.96; N, 11.49.
3,3'-(4,4'-sulfonylbis(4,1-phenylene))bis(2-amino-5-
imino-4-oxo-4,5-dihydro-3 H-chromeno[3,4-c]pyridine-
1-carbonitrile) 24 Yield 77%, melting point >360°C.
IR:υmax./cm
-1 3441, 3348, 3236, 3186 (2NH, 2NH2), 2203
(2 CN), 1680 (2 C=O), 1381, 1153 (SO2).1H-NMR
(DMSO-d6, D2O):δ 6.6 (s, 4 H, 2NH2, exchangable), 7.1-7.9
(m, 16 H, Ar-H), 8.9(s, 2 H, 2NH, exchangable). 13C-NMR
(DMSO-d6): 78.1(2), 112.6(2), 116.7(4), 122.4(2), 122.8(2),
124.6(4), 128.1(2), 128.9(4), 129.1(2), 137.4(2), 155.6(2), 156.1
(2), 158.7(2), 159.6(2), 163.5(2). Anal. Calcd. for C38H22N8O6S
(718.70):C, 63.50; H, 3.09; N, 15.59. Found: C, 63.44; H, 3.18;
N, 15.75.
Molecular docking
All the molecular modeling studies were carried out on
an Intel Pentium 1.6 GHz processor, 512 MB memory
with Windows XP operating system using Molecular
Operating Environment (MOE, 10.2008) software. All
the minimizations were performed with MOE until a
RMSD gradient of 0.05 kcal mol-1Ao-1 with MMFF94X
force field and the partial charges were automatically
calculated. The X-ray crystallographic structure of frane-
syltransferase and arginine methyltransferase (PRMT1)
complexes with their ligands (PDB ID: 3E30, 3Q7E) were
obtained from the protein data bank. The enzymes were
prepared for docking studies where: (i) Ligand molecule
was removed from the enzyme active site. (ii) Hydrogen
atoms were added to the structure with their standard
geometry. (iii) MOE Alpha Site Finder was used for the
active sites search in the enzyme structure and dummy
atoms were created from the obtained alpha spheres.
(iv) The obtained model was then used in predicting
the ligand enzymes interactions at the active site.
In vitro antitumor activity
Human tumor breast cell line (MCF7) was used in this
study. The cytotoxic activity was measured in vitro for
the newly synthesized compounds using the Sulfo-
Rhodamine-B stain (SRB) assay using the method of
Skehan et al. [52]. The in vitro anticancer screening wasdone by the pharmacology unit at the National Cancer
Institute, Cairo University.
Cells were plated in 96-multiwell plate (104 cells/well)
for 24 h before treatment with the compound(s) to allow
attachment of cell to the wall of the plate. Test compounds
were dissolved in dimethyl sulfoxide. Different concentra-
tions of the compound under test (10, 25, 50, and 100 μM)
were added to the cell monolayer. Triplicate wells were
prepared for each individual concentration. Monolayer
cells were incubated with the compound(s) for 48 h at
37°C and in atmosphere of 5% CO2. After 48 h, cells were
fixed, washed and stained for 30 min with 0.4% (wt/vol)
SRB dissolved in 1% acetic acid. Excess unbound dye was
removed by four washes with 1% acetic acid and attached
stain was recovered with Trise-EDTA buffer. Color inten-
sity was measured in an ELISA reader. The relation bet-
ween surviving fraction and drug concentration is plotted
to get the survival curve for breast tumor cell line after the
specified time. The molar concentration required for 50%
inhibition of cell viability (IC50) was calculated and com-
pared to the reference drug Doxorubicin (CAS, 25316-40-9).
The surviving fractions were expressed as means± standard
error and the results are given in Table 3.
Conclusions
Diarylsulfone derivatives may serve as good candidates
in the search for novel anticancer agents as illustrated by
the IC50 values of the investigated compounds. These
values were better than that of Doxorubicin. The mech-
anism of action as anticancer of the synthesized com-
pounds was investigated through molecular docking on
the active site of farnesyl transferase and arginine
methyltransferase. Both enzymes could be the target of
action of these compounds based on the good energy
scores and amino acid interactions in the active sites of
enzymes however, the exact mechanism of action still
needs more investigation to be clarified.
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